Find Reports
Select Report Type
Reimbursement Review
Displaying 376 - 400 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Darolutamide (Nubeqa) for Non-... | Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0196-000 | |||
| dupilumab | Dupixent | dupilumab | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | SR0636-000 | |||
| belimumab | Benlysta | Belimumab | systemic lupus erythematosus | Do not reimburse | Complete | SR0616-000 | |||
| Midostaurin (Rydapt) for Syste... | Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete | PC0193-000 | |||
| Pembrolizumab (Keytruda) for R... | Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0185-000 | |||
| Gemtuzumab Ozogamicin (Mylotar... | Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Reimburse | Complete | PC0190-000 | |||
| Iron (III) Isomaltoside 1000 | Monoferric | Iron (III) Isomaltoside 1000 | iron deficiency anemia | Reimburse with clinical criteria and/or conditions | Complete | SR0622-000 | |||
| sodium zirconium cyclosilicate | Lokelma | sodium zirconium cyclosilicate | Hyperkalemia, adults | Do not reimburse | Complete | SR0612-000 | |||
| safinamide | Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete | SR0617-000 | |||
| ixekizumab | Taltz | ixekizumab | Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | SR0630-000 | |||
| Trifluridine-Tipiracil (Lonsur... | Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0197-000 | |||
| Daratumumab (Darzalex) for Mul... | Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | PC0189-000 | |||
| tafamidis | Vyndaqel | tafamidis | transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | SR0625-000 | |||
| vortioxetine hydrobromide | Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | SR0611-000 | |||
| upadacitinib | Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | SR0614-000 | |||
| Tecentriq for Small Cell Lung ... | Tecentriq | Atezolizumab | Small Cell Lung Cancer (SCLC) | Do not reimburse | Complete | PC0156-000 | |||
| Lorlatinib (Lorbrena) for Non-... | Lorbrena | Lorlatinib | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse | Complete | PC0183-000 | |||
| Trastuzumab Emtansine (Kadcyla... | Kadcyla | Trastuzumab Emtansine | Early Breast Cancer (EBC) | Reimburse | Complete | PC0182-000 | |||
| Cemiplimab (Libtayo) for Cutan... | Libtayo | Cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma (CSCC) | Reimburse with clinical criteria and/or conditions | Complete | PC0187-000 | |||
| glucagon | Baqsimi | glucagon | Severe hypoglycemic reactions | Reimburse with clinical criteria and/or conditions | Complete | SR0626-000 | |||
| Keytruda for Squamous NSCLC – ... | Keytruda | Pembrolizumab | Squamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | PC0176-000 | |||
| inotersen | Tegsedi | inotersen | hereditary transthyretin amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | SR0603-000 | |||
| Lynparza for Newly Diagnosed O... | Lynparza | Olaparib | Newly Diagnosed OC | Reimburse with clinical criteria and/or conditions | Complete | PC0174-000 | |||
| Nerlynx for Hormone Receptor-P... | Nerlynx | Neratinib | ERBB2-positive breast cancer | Do not reimburse | Complete | PC0172-000 | |||
| certolizumab pegol | Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | SR0587-000 |
Health Technology Review
Displaying 376 - 400 of 600
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 376 - 400 of 2132
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| mepolizumab | Reimbursement Review | Not filed | NS0018-000 | ||||
| vorinostat | Reimbursement Review | Not filed | NS0015-000 | ||||
| baloxavir marboxil | Reimbursement Review | Not filed | NS0016-000 | ||||
| icatibant | Reimbursement Review | Not filed | NS0014-000 | ||||
| olaparib | Reimbursement Review | Not filed | NS0013-000 | ||||
| selpercatinib | Reimbursement Review | Complete | PC0264-000 | ||||
| lutetium vipivotide tetraxetan | Reimbursement Review | Complete | PC0297-000 | ||||
| Opioid Analgesics to Treat Chronic Noncancer Pain among Patients Prescribed Opioid Agonist Therapy or With Opioid Use Disorder | Our systematic review examined 5 observational studies on the safety of opioid analgesics alone or with opioid agonist therapy for chronic pain in patients with opioid use disorder or a history of opioid use disorder. | Health Technology Review | Systematic Review | Completed | RE0045-000 | ||
| estradiol and progesterone | Reimbursement Review | Complete | SR0697-000 | ||||
| amifampridine | Reimbursement Review | Complete | SR0660-000 | ||||
| cannabidiol | Reimbursement Review | Complete | SR0798-000 | ||||
| inebilizumab | Reimbursement Review | Complete | SR0793-000 | ||||
| dexamethasone intravitreal implant | Reimbursement Review | Complete | SR0739-000 | ||||
| upadacitinib | Reimbursement Review | Complete | SR0730-000 | ||||
| Auditory Verbal Therapy for Children with Hearing Loss | Health Technology Review | Rapid Review | Completed | RC1542-000 | |||
| Optimizing ultrasound booking schedules | Health Technology Review | In Progress | CM0021-000 | ||||
| Somatropin | Health Technology Review | Technology Review | Completed | HC0068-000 | |||
| Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy | Our utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada. | Health Technology Review | Technology Review | Complete | HC0063-000 | ||
| fidaxomicin | Reimbursement Review | Withdrawn | SF0847-000 | ||||
| nirmatrelvir/ritonavir | Reimbursement Review | Complete | SR0808-000 | ||||
| Optimal installation of DI equipment | Health Technology Review | In Progress | CM0013-000 | ||||
| Appraisal of RWE submitted for health technology assessment | Health Technology Review | In Progress | MG0028-000 | ||||
| PET-CT Comparisons 2020-2024 | Health Technology Review | In Progress | CM0006-000 | ||||
| Cystic Fibrosis | Health Technology Review | In Progress | HM0005-000 | ||||
| Natural Cycles App as Contraception | Horizon Scan | Health Technology Update | In Progress | EN0057-000 |